Philadelphia Trust Co. Makes New $589,000 Investment in CryoPort, Inc. $CYRX

Key Points

• Philadelphia Trust Co. invested approximately $589,000 in CryoPort, acquiring 96,836 shares of the company's stock in the first quarter.
• In the most recent quarterly earnings report, CryoPort reported a net revenue of $45.45 million, surpassing consensus estimates, but had an earnings per share loss of ($0.29).
• Recent analyst upgrades suggest a bullish outlook, with firms like Leerink Partners giving CryoPort an "outperform" rating and setting a price target of $16.00.

Philadelphia Trust Co. purchased a new position in CryoPort, Inc. (NASDAQ:CYRX - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 96,836 shares of the company's stock, valued at approximately $589,000. Philadelphia Trust Co. owned about 0.19% of CryoPort as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in CYRX. Cadian Capital Management LP boosted its stake in shares of CryoPort by 14.1% during the 4th quarter. Cadian Capital Management LP now owns 4,927,027 shares of the company's stock valued at $38,332,000 after purchasing an additional 609,021 shares in the last quarter. Millennium Management LLC boosted its stake in shares of CryoPort by 11.0% during the 4th quarter. Millennium Management LLC now owns 4,139,869 shares of the company's stock valued at $32,208,000 after purchasing an additional 409,353 shares in the last quarter. Silvercrest Asset Management Group LLC boosted its stake in shares of CryoPort by 77.0% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 742,914 shares of the company's stock valued at $5,780,000 after purchasing an additional 323,216 shares in the last quarter. Readystate Asset Management LP boosted its stake in shares of CryoPort by 91.6% during the 1st quarter. Readystate Asset Management LP now owns 500,344 shares of the company's stock valued at $3,042,000 after purchasing an additional 239,153 shares in the last quarter. Finally, Nuveen LLC bought a new stake in shares of CryoPort during the 1st quarter valued at about $743,000. Institutional investors own 92.90% of the company's stock.

CryoPort Stock Down 0.3%

NASDAQ CYRX traded down $0.0270 during trading hours on Wednesday, reaching $8.6930. 365,645 shares of the company's stock traded hands, compared to its average volume of 537,212. CryoPort, Inc. has a 52-week low of $4.58 and a 52-week high of $9.48. The firm has a market cap of $435.26 million, a PE ratio of 6.54 and a beta of 1.88. The firm has a 50-day simple moving average of $7.52 and a 200 day simple moving average of $6.61. The company has a debt-to-equity ratio of 0.39, a current ratio of 16.24 and a quick ratio of 15.47.

CryoPort (NASDAQ:CYRX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.09). CryoPort had a net margin of 37.21% and a negative return on equity of 9.79%. The business had revenue of $45.45 million for the quarter, compared to analysts' expectations of $41.74 million. CryoPort has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that CryoPort, Inc. will post -0.99 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on CYRX shares. KeyCorp raised shares of CryoPort from a "sector weight" rating to an "overweight" rating and set a $15.00 target price on the stock in a research note on Wednesday, August 6th. Stephens started coverage on shares of CryoPort in a research note on Tuesday, July 22nd. They set an "overweight" rating and a $13.00 target price on the stock. Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 target price on shares of CryoPort in a research note on Thursday, May 8th. Morgan Stanley cut their target price on shares of CryoPort from $8.00 to $7.00 and set an "equal weight" rating on the stock in a research note on Monday, May 5th. Finally, Leerink Partnrs raised shares of CryoPort from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $12.00.

Insider Activity

In other CryoPort news, Director Robert J. Hariri sold 12,500 shares of CryoPort stock in a transaction dated Wednesday, May 28th. The shares were sold at an average price of $6.10, for a total value of $76,250.00. Following the completion of the transaction, the director directly owned 8,061 shares of the company's stock, valued at approximately $49,172.10. The trade was a 60.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Edward J. Zecchini sold 51,500 shares of CryoPort stock in a transaction dated Tuesday, June 10th. The stock was sold at an average price of $6.84, for a total transaction of $352,260.00. Following the completion of the transaction, the insider directly owned 90,411 shares of the company's stock, valued at $618,411.24. This trade represents a 36.29% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 490,447 shares of company stock valued at $3,337,198 over the last ninety days. 10.10% of the stock is currently owned by corporate insiders.

CryoPort Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.